We next investigated the mechanisms underlying the clinical relevance of GR in TNBC using MDA-MB-231 TNBC cells that harbour a mutant p53 (ref. 16), as our analysis revealed that TNBC patients exhibit a significantly higher frequency (36.3%) of p53 mutation than other breast cancer patients (9.2%) (Supplementary Fig. 3). Here, NR3C1 is linked to breast carcinoma.